Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7 Million SEK | 110.36% |
| 2022 | 3.32 Million SEK | -1.08% |
| 2021 | 3.36 Million SEK | -38.55% |
| 2020 | 5.47 Million SEK | 10.79% |
| 2019 | 4.94 Million SEK | -39.44% |
| 2018 | 8.15 Million SEK | -47.34% |
| 2017 | 15.49 Million SEK | 13.77% |
| 2016 | 13.61 Million SEK | 458.47% |
| 2015 | 2.43 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.91 Million SEK | 13.06% |
| 2024 Q2 | 7.91 Million SEK | 0.0% |
| 2023 Q3 | 7 Million SEK | 276.35% |
| 2023 Q4 | 7 Million SEK | 0.0% |
| 2023 Q1 | 1.86 Million SEK | -44.11% |
| 2023 Q2 | 1.86 Million SEK | 0.0% |
| 2023 FY | 7 Million SEK | 110.36% |
| 2022 Q4 | 3.32 Million SEK | 0.0% |
| 2022 Q3 | 3.32 Million SEK | 2.83% |
| 2022 Q2 | 3.23 Million SEK | 0.0% |
| 2022 Q1 | 3.23 Million SEK | -3.81% |
| 2022 FY | 3.32 Million SEK | -1.08% |
| 2021 Q1 | 4.09 Million SEK | -25.27% |
| 2021 Q3 | 3.36 Million SEK | -17.77% |
| 2021 FY | 3.36 Million SEK | -38.55% |
| 2021 Q4 | 3.36 Million SEK | 0.0% |
| 2021 Q2 | 4.09 Million SEK | 0.0% |
| 2020 Q4 | 5.47 Million SEK | -0.01% |
| 2020 Q2 | 4.66 Million SEK | -0.01% |
| 2020 Q1 | 4.66 Million SEK | -5.53% |
| 2020 FY | 5.47 Million SEK | 10.79% |
| 2020 Q3 | 5.47 Million SEK | 17.3% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | 4.94 Million SEK | -39.44% |
| 2019 Q4 | 4.94 Million SEK | 0.01% |
| 2019 Q2 | 5.89 Million SEK | 0.0% |
| 2019 Q3 | 4.94 Million SEK | -16.21% |
| 2018 FY | 8.15 Million SEK | -47.34% |
| 2017 FY | 15.49 Million SEK | 13.77% |
| 2016 FY | 13.61 Million SEK | 458.47% |
| 2015 FY | 2.43 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | 36.351% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.738% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.738% |
| Arcoma AB | 33.3 Million SEK | 78.982% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 97.877% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.786% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 97.499% |
| CellaVision AB (publ) | 212.32 Million SEK | 96.703% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | 50.693% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -1.91% |
| C-Rad AB (publ) | 122.4 Million SEK | 94.281% |
| Duearity AB (publ) | 17.53 Million SEK | 60.068% |
| Dignitana AB (publ) | 37.56 Million SEK | 81.366% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 64.646% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.972% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 66.019% |
| Iconovo AB (publ) | 14.55 Million SEK | 51.902% |
| Integrum AB (publ) | 22.07 Million SEK | 68.286% |
| Mentice AB (publ) | 163.55 Million SEK | 95.72% |
| OssDsign AB (publ) | 105.25 Million SEK | 93.349% |
| Paxman AB (publ) | 44.5 Million SEK | 84.273% |
| Promimic AB (publ) | 16.15 Million SEK | 56.672% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 88.74% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 67.102% |
| ScandiDos AB (publ) | 37.18 Million SEK | 81.175% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.574% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 84.113% |
| Senzime AB (publ) | 58.06 Million SEK | 87.944% |
| SpectraCure AB (publ) | 14.97 Million SEK | 53.255% |
| Stille AB | 172.64 Million SEK | 95.945% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.809% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 97.206% |